BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30

• 

  Cardiovascular disease

  Pfizer Mounts Defense of Cardiac Blockbuster as Alnylam, BridgeBio Enter Market

  Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three companies are fighting for new patients.

  April 22, 2025

   · 

  5 min read

   · 

  Nick Paul Taylor
• 

  Breast cancer

  AstraZeneca, Daiichi Sankyo Push Enhertu to Frontline Breast Cancer With Phase III Data

  Analysts at Leerink Partners said in a Monday note that DESTINY-Breast09’s findings “could support an approval” for Enhertu in first-line HER2+ metastatic breast cancer.

  April 22, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Obesity

  Novo Seeks FDA Nod for Semaglutide Pill as Oral Obesity Space Heats Up

  Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according to a company spokesperson.

  April 22, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Manufacturing

  Roche, Regeneron Pledge Multibillion Boosts to US Manufacturing as Trump’s Tariffs Loom

  Roche is committing $50 billion while Regeneron inked a $3 billion manufacturing deal with Fujifilm, allowing the pharma to “nearly double” its U.S. large-scale manufacturing capacity.

  April 22, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Breast cancer

  Gilead’s Trodelvy, With Keytruda, Slows Disease Progression in Triple-Negative Breast Cancer

  Combining Trodelvy with Keytruda and pushing it into the frontline setting could “potentially double” the ADC’s market in metastatic triple-negative breast cancer, according to analysts at Truist Securities.

  April 22, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  C-suite

  Stoffels To Depart Galapagos, Short of Five-Year Mission To Remake the Biotech

  Paul Stoffels left his perch as J&J’s chief scientific officer in 2022 to replace Galapagos’ founding CEO Onno van de Stolpe, inheriting a company that had suffered a series of clinical failures since its 1999 creation.

  April 22, 2025

   · 

  2 min read

   · 

  Annalee Armstrong
• Press Releases

  IQVIA to Announce First-Quarter 2025 Results on May 6, 2025

  April 22, 2025

   · 

  2 min read
• Press Releases

  Sight Sciences to Debut OMNI® Edge Surgical System at the 2025 ASCRS Annual Meeting, Expanding the OMNI Product Portfolio

  April 22, 2025

   · 

  8 min read
• Press Releases

  Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

  April 22, 2025

   · 

  6 min read
• Press Releases

  UPDATE -- AP Biosciences to Present New Preclinical Data at American Association of Cancer Research Annual Meeting

  April 22, 2025

   · 

  2 min read